SVB Leerink Reiterates Market Perform Rating for Design Therapeutics (NASDAQ:DSGN) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Design Therapeutics (NASDAQ:DSGN – Get Free Report)‘s stock had its “market perform” rating reissued by research analysts at SVB Leerink in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $6.00 price target on the stock. SVB Leerink’s price objective would indicate a potential upside of 82.93% from […]
.
Wedbush downgraded Design Therapeutics to a neutral from outperform and cut back its launch timing estimate of genetic disorder drug DT-216 and decreased its discount rate, thereby lowering. -Today at 10:50 am- MarketScreener